CASI Pharmaceuticals Inc (NASDAQ:CASI) posted its quarterly earnings results on Monday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.05.

Shares of CASI Pharmaceuticals (NASDAQ:CASI) opened at 1.6468 on Wednesday. The company has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.22. CASI Pharmaceuticals has a 12-month low of $0.58 and a 12-month high of $1.70. The firm’s market cap is $81.45 million.

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

In other CASI Pharmaceuticals news, Director Wei-Wu He acquired 1,871,605 shares of the stock in a transaction on Monday, October 3rd. The shares were bought at an average price of $1.19 per share, with a total value of $2,227,209.95. Following the acquisition, the director now owns 24,698 shares of the company’s stock, valued at $29,390.62. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Separately, Maxim Group started coverage on CASI Pharmaceuticals in a report on Wednesday, September 21st. They issued a “buy” rating and a $4.00 price target for the company.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

5 Day Chart for NASDAQ:CASI

Receive News & Stock Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.